Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.42 |
| ▸ | F2 | P00734 | 5/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CTSH | P09668 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29720744 | 0.90 | ITGB1 (0.42) | F2ACE | |
| SCHEMBL29630549 | 0.89 | F2 (0.45) | F2OPRK1 | |
| SCHEMBL29590405 | 0.89 | F2 (0.46) | F2RENOPRK1 | |
| SCHEMBL29630379 | 0.86 | REN (0.39) | F2RENOPRK1 | |
| SCHEMBL31634500 | 0.85 | F2 (0.45) | F2OPRK1 | |
| SCHEMBL29591934 | 0.85 | GRB2 (0.43) | APLNRF2CTSLCTSSCTSK | |
| SCHEMBL30563305 | 0.85 | GRB2 (0.44) | F2PTPN1ACEOPRK1 | |
| SCHEMBL29390515 | 0.84 | OPRM1 (0.52) | F2RENOPRK1 | |
| SCHEMBL29531316 | 0.84 | OPRM1 (0.45) | F2OPRK1 | |
| SCHEMBL30563223 | 0.84 | ACE (0.53) | F2ACEOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12257323-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11865192-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3436012-B1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC (US) | 2023-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | MMP8, CD68, ELANE | APLNR 2620/4885F2 1173/4885CTSL 951/4885 |
| US-11865192-B2 | Modified wound dressings | MMP8, CD68, ELANE | APLNR 2620/4885F2 1173/4885CTSL 951/4885 |
| US-12257323-B2 | Modified wound dressings | MMP8, CD68, ELANE | APLNR 2620/4885F2 1173/4885CTSL 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.